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Abstract. A minimum expected gamma (γ) pass rate for VMAT plan verification using 
ArcCHECK was established based on the RTTQA, TG119 test cases and 10 clinical plans with 
varying levels of complexity. The impact of the ‘Measurement Uncertainty’ parameter as 
available in the ArcCHECK software on γ pass rate was studied for both global and local γ 
analysis. Our results show that excluding measurement uncertainty adds tighter tolerance in 
local γ comparison. From the verification of our benchmark cases we established minimum 
expected γ pass rates of 85% and 88% for 2%/2mm global and 3%/3mm local tolerance 
criteria. 
1.  Introduction 
Volumetric Modulated Arc Therapy (VMAT) has been shown to enable more efficient treatment 
delivery compared to conventional static gantry based Intensity Modulated Radiation Therapy (IMRT) 
delivery methods [1, 2]. The efficiency of VMAT comes at the cost of added complexity in the 
treatment planning and delivery stages. The complex nature of VMAT necessitates comprehensive 
three dimensional (3D) dosimetric validation of the plans to ensure dosimetric accuracy of planning 
and delivery [3]. Recently many electronic dosimetric systems have been introduced commercially 
that provide semi-3D or 3D dose information of the delivered treatment plans [4, 5].  
ArcCHECK (Sun Nuclear Corporation (SNC), USA) is one such system which uses diode detectors 
arranged in a helical array in a perspex cylindrical phantom. In routine clinical practice the cumulative 
dose matrix measured by ArcCHECK is compared with the TPS calculated dose in similar geometry 
[4] using gamma analysis [6]. In SNC software in addition to the user defined tolerance criteria an 
additional optional parameter called ‘Measurement Uncertainty’ (e) is provided. The manufacturer 
defines this parameter as follows: “Measurement uncertainties include differences between the 
absolute calibration of the device and the standard dose value due to setup error, temperature change, 
accelerator output fluctuation, array calibration accuracy, and electronic measurement precision. The 
measurement uncertainty (e) is added to the percentage acceptance criterion defined by the user and is 
typically smaller than 1% for the relative comparison and close to 1% for the absolute comparison” 
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[7]. This parameter increases the dose tolerance criteria but does not impact on the distance tolerance 
criteria. The published γ pass rates for VMAT plans using ArcCHECK don’t clearly specify whether 
this parameter is included in the analysis or not [2]. 
In this work we study the impact of this parameter on the local (L) and global (G) γ analysis of the 
ArcCHECK measured and TPS calculated dose matrices. Also we establish a benchmark pass rate 
with different types and level of tolerance criteria to ensure the accuracy of VMAT plans appropriate 
for our centre using the ArcCHECK dosimetric system.  
2.  Materials and Methods 
The Pinnacle, v 9.2, (Philips Ltd, USA)Treatment Planning System (TPS) was used to generate 
VMAT plans using a 6 MV photon beam model for an Elekta Synergy (Elekta Ltd, Crawley, UK) 
Linear Accelerator (linac). Dose calculations for all plans in the study were performed using the 
adaptive convolution dose calculation algorithm. The Synergy accelerator used in this study was 
equipped with an Multi Leaf Collimator (MLCi) head and Integrity v1.1 linac control software.  
2.1.  Benchmark VMAT plans 
Two sets of plans were considered to benchmark the dosimetric accuracy of VMAT plans. The first set 
included recommended test cases from the UK Radiotherapy Trial Quality Assurance (RTTQA) group 
and AAPM Task Group 119 (TG119). This includes the 3D treatment planning system (3DTPS) test 
cases from RTTQA and Mock Prostate, Mock Head and Neck, Multi Target, C shape-easy and C 
shape-hard from TG119 [8, 9]. In the second group 10 clinical cases with varying levels of complexity 
in target volume and dose objectives were selected retrospectively from clinical cases. This included 5 
head and neck, 3 prostate and 2 pelvic nodes cases. The VMAT plans were generated with single full 
arc for simple cases and double full arcs for complex cases. RTTQA and TG119 recommended dose 
objectives were used  for the test cases and for clinical cases the dose objectives prescribed as per 
RTOG guidelines and ICRU83 prescription methodology was used as the achievable aim [10]. 
2.2.  Plan verification and analysis 
The dosimetric accuracy of the generated plans was verified by the following three measurements: 1. 
point dose measurements in high, medium and low dose regions using a CC13 ion chamber in a CIRS 
phantom, 2. Coronal plane dose distribution verification using EBT3 gafchromic film placed in a solid 
water phantom, and 3. Cumulative dose measurement using the ArcCHECK dosimetric system.  
The coronal film measurements were compared with the TPS calculated dose matrices using global 
γ analysis with 3%/3mm (3%G/3mm) tolerance criteria in RIT film dosimetry software. The 
ArcCHECK measured and TPS calculated dose matrices were compared using global and local γ 
analysis with 2%/2mm and 3%/3mm (2%G/2mm, 3%G/3mm and 2%L/2mm, 3%L/3mm) with and 
without the measurement uncertainty parameter included. In order to assess the impact of the 
measurement uncertainty (e) parameter on the tolerance criteria analysis was also performed with 
1%G/2mm, 2%G3mm, 1%L/2mm and 2%L/3mm with the uncertainty parameter. All γ analysis was 
performed with a high dose threshold of 10% and gamma tolerance of 1. 
3.  Results and Discussion 
The generated VMAT plans successfully achieved the dose objectives recommended by the RTTQA 
group and TG119 for all test cases except the C shape hard case. As the aim of the C-shape hard case 
is to test a system that is being pushed very hard this was not unexpected.  
The point dose agreement in the CIRS phantom at high, medium and low dose regions of all 
studied plans resulted in a mean (1σ) percentage difference of -0.5 (1.3)%, 0.5 (1.6)% and -0.6 (3.4) % 
respectively. The coronal plane dose verification using film resulted in a mean (1σ) γ pass rate of 96.6 
(2.7)%. 
Figure 1 shows the local and global γ pass rates with 2%/2mm and 3%/3mm pass rates for studied 
VMAT plans. Figure 2 a, b and c show the gamma analysis results with 3%G/3mm with ‘e’, 
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3%G/3mm without ‘e’ and 2%G/3mm with ‘e’ for 3DTPS test case. Figures 3 a, b and c show similar 
results with local gamma analysis. In the figures the red and blue points show the failed points with 
high and low dose respectively. Table 1 shows the mean (1σ) γ pass rates with local and global γ 
analysis with and without measurement uncertainty in the analysis.  
     
 
Figure1. Gamma pass rate with different tolerance criteria for studied VMAT plans using ArcCHECK. 
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Figure 2. γ pass results for 3DTPS test plan with (a) 
3%G/3mm with ‘e’, (b) 3%G/3mm without ‘e’ and 
(c) 2%G/3mm without ‘e’ tolerance criteria. Red 
and blue points show failed detector points with 
high (red) and low (blue) dose measurements. 
Figure3. γ pass results for 3DTPS test plan with 
(a) 3%L/3mm with ‘e’, (b) 3%L/3mm without ‘e’ 
and (c) 2%L/3mm without ‘e’ tolerance criteria. 
Red and blue points show failed detector points 
with high and low dose measurements. 
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Table 1. Mean (1σ) gamma pass rate of studied VMAT plans with different tolerance criteria.   
 
In general including measurement uncertainty results in higher pass rates both in global and local γ 
comparisons due to the additional dose tolerance added to the user defined dose tolerance. The 
manufacturer states that the measurement uncertainty value is approximately 1% for the γ comparison 
in absolute dose mode. From our results the gamma pass rate for 2%/2mm and 3%/3mm tolerance 
criteria without measurement uncertainty included was not equal to the 1%/2mm and 2%/3mm criteria 
with measurement uncertainty (table 1, figures 1, 2 and 3). Also not including the measurement 
uncertainty in the global tolerance resulted in tighter criteria (reduced pass rate) whereas in local 
tolerance it resulted in more relaxed tolerance criteria (increased pass rate) (table 1).  
While there is a lack of evidence between the correlation of acceptable gamma pass rate and 
clinical significance, 95% pixels passing the global γ analysis with 3%/3mm tolerance criteria 
(3%G/3mm) is considered to be widely acceptable in clinical practice. Many of the IMRT and VMAT 
credentialing bodies also follow this. Nelms et al show that 2%L/2mm has been shown to more 
closely reflect the clinically significant errors in treatment plans compared to the more generous 
3%G/3mm criteria [11]. Similarly to the ArcCHECK software, Nelms et al also included measurement 
uncertainty in the analysis. Our results show that excluding measurement uncertainty adds a tighter 
tolerance in local γ comparison. From the verification of our benchmark cases we set a γ pass rate of 
mean-2σ as our minimum expected pass rate for clinical VMAT plans. Based on this we set minimum 
pass rate of 85% and 88% for 2%G2mm and 3%L/3mm tolerance criteria respectively noting that 
higher pass rates are expected for simple plans.  
4.  Conclusion 
Exclusion of the measurement uncertainty parameter results in a tighter tolerance in local γ 
comparison of the ArcCHECK dose verification. Based on the verification of our benchmark plans we 
set γ pass rates of 85% and 88% as minimum expected pass rates for our clinical VMAT plans for 
2%G/2mm and 3%L/3mm tolerance criteria.    
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Measurement 
uncertainty 
Tolerance criteria 
2%G/2mm 3%G/3mm 2%L/2mm 3%L/3mm 
Included 96.1(3.0) 99.6(0.5) 89.8(5.6) 97.0(2.4) 
Not included 93.1(4.6) 99.0(1.1) 83.7(7.1) 94.9(3.5) 
 1%G/2mm 2%G/3mm 1%L/2mm 2%L/3mm 
Included 91.5(4.7) 98.6(1.5) 87.9(5.9) 96.2(2.8) 
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